Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL292420 | 1.00 | HRH3 (0.46) | HRH3CXCR4 | |
| SCHEMBL1879610 | 0.94 | CXCR4 (0.51) | HRH3CXCR4 | |
| SCHEMBL448349 | 0.94 | CXCR4 (0.51) | HRH3CXCR4 | |
| SCHEMBL3979376 | 0.94 | CXCR4 (0.51) | HRH3CXCR4 | |
| SCHEMBL26576209 | 0.88 | CXCR4 (0.50) | HRH3CXCR4 | |
| SCHEMBL4389003 | 0.87 | — | — | |
| SCHEMBL2639396 | 0.87 | — | — | |
| SCHEMBL4387638 | 0.87 | — | — | |
| SCHEMBL23828676 | 0.87 | HRH3 (0.52) | HRH3CXCR4 | |
| SCHEMBL23828668 | 0.87 | HRH3 (0.52) | HRH3CXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2321319-B1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES INC (US) | 2012-03-14 | — | — | EP | disclosed |
| US-7998950-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2011-08-16 | — | — | US | disclosed |
| EP-2321319-A1 | ANTIVIRAL COMPOUNDS | Gilead Sciences, Inc. (US) | 2011-05-18 | — | — | EP | disclosed |
| WO-2010011959-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2010-01-28 | — | — | WO | disclosed |
| US-20100022508-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022508-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | HRH3 3642/4885CXCR4 1543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.